Monthly Archives: February 2022

EDMONTON, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bharat Sharma, marriage counsellor of Edmonton Counselling Services, Alberta, has won the 2022ThreeBestRatedaward because of his services with sensitivity, responsiveness, and respect for individuals and couples struggling with anxiety, depression, addiction, relationships or other issues. And he has faced a rigorous 50-point inspection of ThreeBestRated including history, complaints, and satisfaction.

About Bharat Sharma:

Bharat Sharma is an Indian-Canadian therapist,and he is a prominent advocate for mental health issues in Edmonton, Alberta. His work has made him one of the best-known and leading figures in mental health and alternative medicine.Sharma earned a Doctor of Medicine in alternative medicine and a Master of Social Work degree equivalency in Alberta. As a Master Practitioner in Clinical Counselling, Canadian Clinical Supervisor in Addiction, and a qualified Substance Abuse professional, he brings real-life experience, values, and formal training to help his patients get to a better place in their life.

Edmonton Counselling Services:

In 2015, Bharat Sharma foundedEdmonton Counselling Services, and he has dedicated his career to helping couples, individuals, and families struggling with everyday life issues, including addictions, mental well-being, anger management, grief, relationship problems, and self-esteem issues in Edmonton, Alberta, Canada. Sharma believes that the mind affects the thought processes, mental state, and body. He considers people might be initially uncertain about seeking out help and support for mental health for personal reasons but, when they do, they will feel confident that they are taking a bold first step towards getting to a better life and being a better person.

Counselling Approaches:

Those in need ofcouples counselling will find assistance with communication, conflict, affairs, and emotional distancing. Thousands of individuals have benefited from his treatments in Edmonton and the surrounding area.

However, no marriage can last forever in peace and contentment; there will always be disputes. In such situations, people can seek counselling in order to keep the relationship alive. Hence,Sharma's mission is to provide his patients with the best therapy available through a multi-disciplinary approach, including body, mind, and spirit treatment in a holistic way. He accomplishes it through a unique combination of complementary alternative and counselling approaches.

In need of any counselling services? Visit https://edmontoncounsellingservices.ca/about/. Sharma's clinic is located in Cedars Professional Park, 2923 66 St. NW, Edmonton, T6K 4C.

CONTACT:Bharat Sharma780 328 7706

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Read the original:

Bharat Sharma Was Named Top Marriage Therapist in Edmonton, - GlobeNewswire

Doctors are professionals. They're also people. Some of the things patients say can be frustrating on both counts. The worst-case scenario for everyone involved is that such crossed wires can lead to less-than-optimal care. To make the most of your doctor-patient relationship, they say, be an active participant in your care and an open communicatorbut some things are better left unsaid when seeking a doctor's care. Read on to find out moreand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Being dishonest with your doctor can put your health on the line. "Do not ever hide anything from a doctor," advises Chaye McIntosh, clinical director of ChoicePoint Health in Fair Lawn, New Jersey. "From your symptoms to your lifestyle and diet, share everything with a doctor verbally. Also, I can't emphasize how important it is to communicate any mistake you've made, like missing your medication. Communicate thatdon't hide it because of fear."

Virtual doctor's visits are now more available than ever. They can be a boon for your healthif you don't risk your life during your appointment. "With the rise of telemedicine, the worst thing a patient can say during an appointment is 'I'm driving right now'," says Rajinder Chahal, MD, a California-based endocrinologist and founder of WhiteCoatRemote.com, a telemedicine job board. "This is dangerous. I've had to ask many patients to pull over while driving to do the appointment. It's important to treat a telehealth appointment with the same respect as an in-person one to get the most out of your visit."

According to the medical journal Therapeutics and Clinical Risk Management, more than 40% of people risk their health by misunderstanding, forgetting, or ignoring healthcare advice, says Maria Ortiz-Tweed, MD, a pediatrician in Tampa, Florida. "As a pediatrician, not only do I take care of my young patients, but I always seek to gain the trust of their parents," she adds. "When it comes to treatment recommendations, there are times when parents refuse and start 'bargaining' about alternative treatments they consider to be better. Yes, nowadays parents are more aware of medical issues because of the internet, but that doesn't necessarily mean that the information they find is reliable and accurate."

But staying silent about your questions or concerns won't lead to optimal care, either. "Some patients simply accept a doctor's opinion, appear to accept it, then don't take medication or don't show up for the next appointment," says neuro-ophthalmologist Bradley J. Katz, MD, Ph.D., of Axon Optics. "If you disagree with the doctor or have a concern, raise it. Otherwise, the doctor doesn't have the opportunity to explain to you why they diagnosed you a certain way or made certain recommendations, and you might not be making the best health decisions for yourself as a result."

Doctors have long been frustrated by the growing epidemic of self-diagnosis, a phenomenon they call Doctor Google. Coming in a close second these days: Doctor Instagram. "My field of medicine perhaps lends itself most widely to research done on Instagram and TikTok before a patient's visit," says Noreen Galaria, MD, FAAD, a board-certified dermatologist in Northern Virginia. She advises never saying things like, "On Instagram, I read that I actually shouldn't be using this prescription" or "There's an influencer I follow that says never to use that."

"In my practice, we manage spider and varicose veins, and sometimes we hear patients say, 'Is it really worth that much?'" says Faisal Siddiqi, MD, FACC, a New Jersey-based cardiologist. "That is an incredibly difficult question and puts us in an awkward position to defend our value. As a vein specialist, we might be a little different than your visit to the primary care office. A considerable amount of time goes into treatment and the things that go on behind the scenes to make a quality practice. I would recommend saying, 'I really would like to have you perform my treatments. Are there any special offers available at this time?'" And to get through this pandemic at your healthiest, don't miss these 35 Places You're Most Likely to Catch COVID.

Follow this link:

Never Say These Words to Your Doctor, Say Experts Eat This Not That - Eat This, Not That

31 January 2022

Director of the Progress Educational Trust and commissioning editor of its flagship publication BioNews

There has been much professional and public debate about the use of so-called fertility treatment 'add-ons' over the years. The Progress Educational Trust's event 'Adding Up What We Know: A Global Perspective on Fertility Treatment Add-Ons' brought together an international lineup of speakers to share their knowledge and broaden the discussion.

Dr Kersti Lundin director of Sahlgrenska University Hospital's Reproductive Medicine Laboratory, and co-chair of the European Society for Human Reproduction and Embryology (ESHRE)'s working group on add-ons opened the discussion by setting out what add-ons are. They are something 'not essential for treatment, but optional interventions added on top, most often at an additional cost' she said.

Dr Lundin explained that there are a wide range of treatment add-ons on offer; including different tests, drugs, holistic or alternative therapies, 'special' equipment, laboratory techniques and surgical interventions. It is claimed that these improve pregnancy or live birth rates, reduce the risk of miscarriage, or shorten the time to pregnancy.

ESHRE has set up a working group to produce recommendations for professionals, patients and policymakers, with the aim of ensuring that all fertility patients receive safe and evidence-based treatment. Some 33 add-ons have been identified and stratified into different categories diagnostic tests, laboratory interventions, clinical management and 'selective' add-ons. Dr Lundin said that 'selective' add-ons were treatments which are clinically appropriate for some patients for example, intracytoplasmic sperm injection (ICSI) for male factor fertility which should not be used for all patients.

The next panellist was Dr Manuela Perotta, a senior lecturer in technology and organisation at Queen Mary University of London and principal investigator at the Remaking the Human Body project (which is funded by Wellcome). Dr Perotta presented some of the findings from this project.

Anyone still in any doubt about the proliferation of add-ons would have those doubts pushed aside on hearing the results of a survey that Dr Perrotta and her team had carried out. Patients reported on the add-ons they had used, been offered or considered using. She showed a very busy word cloud which listed around 60 procedures believed by some to be add-ons, ranging from endometrial scratch to DNA karyotyping.

The focus of Dr Perrotta's talk was differences in perceptions of add-ons between professionals, patients and patients' partners. Some professionals considered something to be an add-on depending on whether and how it was itemised on the bill given to a paying patient, while others thought there should be distinctions as to how an add-on was regulated depending on how invasive the particular treatment was.

There were very wide-ranging findings when it came to patients' perceptions. Some patients extensively researched add-ons and sought them out, while others wanted to delegate decisions about their treatment including add-ons to the medical professionals. The postcode lottery relating to state funding of fertility treatment leads to some NHS patients being treated in private clinics and some self-funded patients being treated in NHS clinics, making it yet more difficult to decide what is and isn't an add-on in the UK. Furthermore, if a patient has only a very limited opportunity for state-funded treatment, then they are understandably liable to try everything possible to help the treatment work.

Dr Perrotta discussed the Human Fertilisation and Embryology Authority (HFEA)'s traffic light system for assessing add-ons. Her research had uncovered a number of issues for patients with the current system perhaps most significantly, the fact that many of them are not aware of it. Other patients did find the HFEA's information during the course of their extensive online research, but even then, they did not necessarily feel equipped to evaluate the advisability of add-ons in their specific situation.

Dr Perrotta argued that the HFEA's traffic lights need to be more visible, need to present information about other relevant criteria besides live birth rates (for example, of miscarriage rates) and should make it possible for patients to explore multiple layers of information about evidence.

We moved from the UK to Australasia with the next speaker, Dr Sarah Lensen an editor at Cochrane's Gynaecology and Fertility Group, where she was responsible for the Cochrane Special Collection 'IVF: Effectiveness of Add-Ons and Research', and also a research fellow at the University of Melbourne. Australia has one of the highest uses of IVF per capita in the world, with just over 2600 cycles per million per year being carried out. There is however, little data relating to add-ons from the Australia and New Zealand Assisted Reproduction Database.

Dr Lensen and her team investigated the add-ons by assessing clinic websites in Australia and New Zealand, and found that 78 percent of clinic websites offered add-ons. There were 21 different add-ons on offer (using these researchers' definition of an add-on), the cost of which ranged from no extra charge to around 2000. PGT-A, time lapse and assisted hatching were the add-ons most commonly listed, and most descriptions of add-ons contained statements about the add-ons' supposed benefits.

A patient survey relating to the prevalence, offer and use of add-ons was then carried out. There were 1600 responses, and 82 percent of respondents had used an add-on. The most commonly used add-on was acupuncture specifically intended to accompany fertility treatment (see BioNews 1107), followed by PGT-A and Chinese herbal medicine. Most people who had used an add-on had heard about it from their fertility specialist, who raised it during a consultation.

Dr Lensen concluded her presentation with some interesting research on the use of endometrial scratch. In 2015, her team found that 83 percent of clinicians offered endometrial scratch, with 73 percent believing it to be beneficial for recurrent implantation failure. During the intervening years, the use of endometrial scratch has not been backed up by evidence. Research carried out in 2020 showed that only 34 percent were now offering this treatment, with 24 percent believing it to be beneficial (see BioNews 1126).

Back to Europe for the next speaker, Satu Rautakallio-Hokkanen, who is chair of Fertility Europe (an umbrella group of 26 fertility patient organisations) and also secretary of Infertility Association Simpukka (which is based in Finland). She gave the all-important patient perspective, which is key to understanding the use and prevalence of add-ons. We learned how despair, ignorance and desperation for information feed into the uptake of add-ons. Rautakallio-Hokkanen and colleagues had conducted a survey which found that 55 percent of patients found out about add-ons from the internet, and 93 percent wanted to find out more about them. The main driver, she suggested, is that add-ons provide hope.

Worryingly, 49 percent stated that they didn't know or didn't understand the benefits of the relevant add-on, but still wanted to try it. More worryingly still, 65 percent could not say whether they thought the add-on was safe or not. Rautakallio-Hokkanen called for more respect to be shown to patients and an end to the exploitation of their despair. Patients need proven treatments and an honest discussion about the risks and benefits, she said.

Next we hopped over the pond to the USA, to hear from Dr Sigal Klipstein chair of the American Society for Reproductive Medicine (ASRM)'s Ethics Committee, and an obstetrician/gynaecologist at InVia Fertility in Chicago.

Dr Klipstein outlined the recent publication Moving Innovation to Practice, in which the ASRM Ethics Committee emphasises that evidence of safety and effectiveness is necessary, before dissemination of new interventions into clinical practice. Dr Klipstein said that the key question for patients should be 'Will this particular treatment benefit me?'. She said that some patients feel lucky to stumble upon the only clinic that offers 'treatment X', but they should question this if treatment X is so great, why aren't more clinics offering it? She used an amusing made-up study to illustrate how easily studies can be skewed by small sample sizes and cherrypicking patient groups.

Dr Klipstein concluded by challenging the audience with a series of fundamental questions. If a patient asks for an add-on and is willing to pay, and their doctor acquiesces, is this acquiescence tantamount to implicit approval? Does it give false hope or? Conversely, if the doctor declines to offer the requested treatment, is this paternalistic? Or is it actually good medical care?

The final speaker was Peter Thompson, chief executive of the HFEA. He welcomed the fact that there is now more global discussion of add-ons than was previously the case, with different professional bodies taking an interest. What the HFEA aims to do, he said, is to provide impartial and independent evidence and information on add-ons for professionals and patients. One of the major challenges has been how to explain complex and subtle issues in a simple but meaningful way, such that it is accessible.

The HFEA's current traffic light system rates 11 add-ons, and assesses add-ons according to one key criterion - is the treatment under consideration proven to be effective, for most fertility patients, in increasing their chances of having a baby?

The HFEA is looking at reviewing and refining the traffic light system, and will be carrying out a consultation on this in future. As there are currently no 'green' rated add-ons listed on the HFEA website, this may lead some patients to view an 'amber' rating as a recommendation, rather than (as is intended) a warning to be cautious. So perhaps changes in presentation are warranted. Another area that Thompson mentioned reviewing was the evidence base used for the rating system - this relies on randomised controlled trials, which is arguably problematic when there is a dearth of such trials. The final consideration is whether to change the measure of success from improving the live birth rate to reducing miscarriage, or reducing time to pregnancy.

After these opening presentations, the audience asked questions about whether and when ICSI should be considered an add-on, a lack of awareness among patients of the risks posed by some add-ons, and the fact that some patients are not even aware that they are using an add-on. There was clear agreement among the speakers that it should not be the responsibility of the patient to ask about risks.

One of the main take-home messages was the need for shared decision-making, so that while patients' voices are heard and taken into account, doctors do not abrogate their responsibility. Fertility doctors must be prepared to give patients unpalatable advice, about why certain treatments may not be appropriate.

PET is grateful to the team at the Remaking the Human Body project (which is based at Queen Mary University of London and funded by Wellcome) for supporting this event. Our next online events will be:

Go here to read the rest:

Adding Up What We Know: A Global Perspective on Fertility Treatment Add-Ons - BioNews

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023

Reaffirms ANTHIM as an important medical countermeasure in the U.S. governments strategy to maintain sufficient quantities of anthrax anti-toxin to effectively respond to an anthrax emergency

PARSIPPANY, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Elusys Therapeutics, Inc. (Elusys) announced today that it has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for use against a potential anthrax attack.

Elusys is pleased to continue its successful track record of supplying a critical medicine to treat the deadly effects of anthrax exposure, said Elizabeth Posillico, president and chief executive officer of Elusys. ANTHIM is a key therapeutic in the U.S. governments preparedness strategy to protect the U.S. population against natural and man-made biothreats.

The contract for the procurement of ANTHIM consists of a base period of performance, valued at $50 million, which has been fulfilled. The contract includes options valued up to $31 million. If all options are exercised, the total contract value will be $80,864,000 with completion of the contract expected by the first half of 2023. Contract 75A50121C00073 is funded by HHS ASPR.

As previously announced, Elusys has executed a definitive merger agreement with Heat Biologics, Inc. (NASDAQ: HTBX), pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. The acquisition is expected to close during the first quarter of 2022 and is subject to customary closing conditions.

About ANTHIMANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIMs toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. ANTHIM is supplied as single-dose vials for IV infusion.

Story continues

ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis.

Anthrax is a life-threatening infectious disease caused by Bacillus anthracis. Cases of inhalational anthrax in humans can occur through intentional spread of B. anthracis spores as a biowarfare or bioterrorism agent. B. anthracis spores introduced through the lungs lead to inhalational anthrax, which is deadly in humans.

IMPORTANT SAFETY INFORMATION Including BOXED WARNING

WARNING: HYPERSENSITIVITY and ANAPHYLAXISHypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion. ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs.

WARNINGS AND PRECAUTIONSHypersensitivity and anaphylaxis have been reported during the IV infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs. Pre-medication with diphenhydramine is recommended prior to administration of ANTHIM. Diphenhydramine pre-medication does not prevent anaphylaxis and may mask or delay onset of symptoms of hypersensitivity.

ADVERSE REACTIONS The safety of ANTHIM has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax. The most frequently reported adverse reactions were headache, pruritus, infections of the upper respiratory tract, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in extremity.

USE IN SPECIFIC POPULATIONSPediatric Use: There have been no studies of the safety or PK of ANTHIM in the pediatric population.

To see the complete prescribing information for ANTHIM, click here.

About Elusys Therapeutics Elusys, based in Parsippany, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. ANTHIM(obiltoxaximab) Injection, the companys monoclonal antibody (mAb) anthrax antitoxin, received market clearance by the U.S. Food and Drug Administration (FDA) in March 2016. In July 2020, Health Canada approved ANTHIMs New Drug Submission (NDS) for the treatment of inhalation anthrax. ANTHIM has also received marketing approved in the E.U. and the U.K., under the trade name of Obiltoxaximab SFL. For more information, please visit http://www.elusys.com.

CONTACT: Elizabeth PosillicoElusys Therapeutics, Inc.t: 973.808.0222e: eposillico@elusys.com

Go here to read the rest:

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human...

Chris Howe, the founder of The Voice of Healing, is offering the Healing Handprint for free to bring positive life transformations.

Chris Howe, an experienced alternative healer and the founder of The Voice of Healing, announced that hes giving free Absent Healing using the Power of the Healing Hand. Interested parties can download the healing handprint at Chriss website, place their hand on the print for 15 minutes every day, and experience positive mental and physical transformations.

Absent Healing is a form of ancient alternative medicine centred on restoring health by non-physical means. The idea is to restore the balance in the mind, body, and soul and remove the blockages in ones energy field.

Using the healing handprint as a medium, Chris can connect with anyone around the world and send his healing energy to restore the free flow of energy in ones body, starting the process of self-healing. The right handprint delivers positive energy, while the left handprint draws negative energy.

Chriss Healing Hand has had over 2 million downloads since its initial launch. Many experienced improved physical and mental health, some of whom had their ailments healed or gone without a trace.

Those healing handprints really made a difference.

The tumour completely disappeared a change doctors could only put down to Chris.

Interested individuals can connect with Chris Howe and learn more about absent healing and alternative therapy here:https://www.thevoiceofhealing.co.uk.

Media ContactCompany Name: The Voice of HealingContact Person: Christopher HoweEmail: Send EmailPhone: +44 7774817513Country: United KingdomWebsite: https://www.thevoiceofhealing.co.uk/

See original here:

The Voice of Healing Brings Back the Healing Handprint to the Web - Digital Journal

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023

Reaffirms ANTHIM as an important medical countermeasure in the U.S. governments strategy to maintain sufficient quantities of anthrax anti-toxin to effectively respond to an anthrax emergency

PARSIPPANY, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Elusys Therapeutics, Inc. (Elusys) announced today that it has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for use against a potential anthrax attack.

Elusys is pleased to continue its successful track record of supplying a critical medicine to treat the deadly effects of anthrax exposure, said Elizabeth Posillico, president and chief executive officer of Elusys. ANTHIM is a key therapeutic in the U.S. governments preparedness strategy to protect the U.S. population against natural and man-made biothreats.

The contract for the procurement of ANTHIM consists of a base period of performance, valued at $50 million, which has been fulfilled. The contract includes options valued up to $31 million. If all options are exercised, the total contract value will be $80,864,000 with completion of the contract expected by the first half of 2023. Contract 75A50121C00073 is funded by HHS ASPR.

As previously announced, Elusys has executed a definitive merger agreement with Heat Biologics, Inc. (NASDAQ: HTBX), pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. The acquisition is expected to close during the first quarter of 2022 and is subject to customary closing conditions.

About ANTHIMANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIMs toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. ANTHIM is supplied as single-dose vials for IV infusion.

ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis.

Anthrax is a life-threatening infectious disease caused by Bacillus anthracis. Cases of inhalational anthrax in humans can occur through intentional spread of B. anthracis spores as a biowarfare or bioterrorism agent. B. anthracis spores introduced through the lungs lead to inhalational anthrax, which is deadly in humans.

IMPORTANT SAFETY INFORMATION Including BOXED WARNING

WARNING: HYPERSENSITIVITY and ANAPHYLAXISHypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion. ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs.

WARNINGS AND PRECAUTIONSHypersensitivity and anaphylaxis have been reported during the IV infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs. Pre-medication with diphenhydramine is recommended prior to administration of ANTHIM. Diphenhydramine pre-medication does not prevent anaphylaxis and may mask or delay onset of symptoms of hypersensitivity.

ADVERSE REACTIONS The safety of ANTHIM has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax. The most frequently reported adverse reactions were headache, pruritus, infections of the upper respiratory tract, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in extremity.

USE IN SPECIFIC POPULATIONSPediatric Use: There have been no studies of the safety or PK of ANTHIM in the pediatric population.

To see the complete prescribing information for ANTHIM, click here.

About Elusys Therapeutics Elusys, based in Parsippany, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. ANTHIM(obiltoxaximab) Injection, the companys monoclonal antibody (mAb) anthrax antitoxin, received market clearance by the U.S. Food and Drug Administration (FDA) in March 2016. In July 2020, Health Canada approved ANTHIMs New Drug Submission (NDS) for the treatment of inhalation anthrax. ANTHIM has also received marketing approved in the E.U. and the U.K., under the trade name of Obiltoxaximab SFL. For more information, please visitwww.elusys.com.

CONTACT: Elizabeth PosillicoElusys Therapeutics, Inc.t: 973.808.0222e: eposillico@elusys.com

Excerpt from:

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM, Its Treatment for Inhalation Anthrax, to the US Department of Health and Human Services...

The pandemic triggered the rise of mental health cases all around the world. It has been one of the most pressing concerns in the medical field, which is why experts have been trying to discover alternative and effective ways to treat mental healtha field where Sonia Singh is an expert.

Sonia Singh, LCSW, LCADC, popularly recognized by her trademarked name, The Happy Therapist, is a psychotherapist, as well as the founder of the Center of Inner Transformations, an alternative mental health and substance use treatment agency and wellness center that provides unique programming and services that address various psychological, emotional, and wellness needs. One of the Center of Inner Transformations premier programs includes the use of herbal and plant-based medications, also integrative evidence-based practices that have been researched, studied, and tested to be effective alternative solutions to treating mental health. Many of Ms. Sonia Singhs treatment methods are drawn from both modern and ancient, natural and holistic interventions that assist her clients in healing themselves with realistic and sustainable coping tools.

Plant-based health solutions and naturopathic healing has become a trend in recent years. Because of the rise of plant-based available foods and the advancement of public awareness campaigns about the long-term, harmful physiological effects of pharmaceutical medicines, people are more conscious of what they are consuming and how this affects their health. Traditional mental health treatments are very outdated and ineffective. Most mental health providers, me included, were initially trained with a strong foundation in modern, traditional mental health theories and treatment interventions. Much of which incorporates the use of pharmaceutical psycho-tropic medications, medication management, and related counseling. However, everything that a clinician learns after that traditional and ordinary training to help their clients overcome the issues that they present during their treatment is up to the perspectives of that clinician. Ive taken the path of focusing on what I call real wellness. This incorporates the use of natural elements and holistic mind, body, and spirit interventions to aid the mental and emotional healing process, says Ms. Sonia Singh, The Happy Therapist. People want long-term solutions. They want to change and transform their situations. They dont want to place a temporary band aid on their issues. They want real long-term change and they want to feel better.

Sonia Singh has focused the development of the Center of Inner Transformations to be a leader in alternative therapies, by including the use of plant-based medicines, supplements, and specific natural foods, plants and herbs, some of which may cause mild states of psychosis or euphoria. For certain mental health patients, primarily those people who struggle with a history of severe trauma or debilitating anxiety, natural alternatives are more desirable. They produce less to no negative long-term effects when used at an adult stage in life. The effects of a plant-based treatment protocol better corresponds with our bodies internal systems like a lock and key to aid healing. When we use natural elements from the earth as a part of our path to curing our health issues, we are giving ourselves life to live, Ms. Sonia Singh passionately states. My alternative programming provides choices. My clients choose which mind-altering substance they want to incorporate as a part of their treatment. Whether a psycho-tropic pharmaceutical medication or a plant-based medicine, supplement or wellness plan. They choose. The Center of Inner Transformations provides mental health interventions that may incorporate wellness treatment planning that focuses on harm reduction while combining holistic intervention and plant-based foods and medicines.

Ms. Sonia Singh is first-generation American-Punjabi, New York City native, and New Jersey resident who began her psychotherapeutic career in New Jersey close to her Alma Mater at Rutgers University. She directs several psychological and addiction treatment programs and has developed a line of wellness products and services that support her agencys mission to incorporate nature and holistic based treatment options.

The Center of Inner Transformations is a leading alternative mental health and substance use treatment agency that aims to address the opioid epidemic by influencing a culture that addresses their mental health concerns with naturopathic, holistic and safe treatment methods.

Media ContactCompany Name: Center of Inner TransformationsContact Person: Sonia SinghEmail: Send EmailPhone: (732) 508-0052Country: United StatesWebsite: http://www.centerofinnertransformations.com

Read this article:

Plant-Based Psychosis Inducing Alternative Mental Health Treatments Introduced by The Happy Therapist Sonia Singh - Digital Journal

A high blood pressure diet does not have to entail eating bland foods. Turning to Eastern culture, scientists have discovered a powerful bean which reduces the activity of angiotensin-converting enzyme (ACE) that constricts blood vessels resulting in high blood pressure.

Mung beans are tiny, oval-shaped beans are available in several forms, with the peeled version popular in Indian dishes, and the processed version of bean sprouts and starch noodles more common in Asian cuisine.

In a study published in the journal Human and Experimental Toxicology, scientists discovered that mung beans are highly effective at inhibiting LDL oxidation due to their potent free-radical scavenging properties.

The versatile mung bean has also been shown to target another significant cardiovascular disease risk factor in high blood pressure.

Hypertensive rats supplemented with mung bean sprout extracts for one month experienced significant reductions in systolic blood pressure.

Mung beans have a high concentration of phenols and protein fragments called peptides which help to reduce the activity of angiotensin-converting enzyme (ACE) that constricts blood vessels resulting in high blood pressure.

Recent studies involving 58,000 men and women aged 40-79 found that those with the lowest intakes of dietary magnesium had a 51 percent increased risk of heart disease mortality compared to those with the highest intakes.

Mung beans significantly improve magnesium levels and help to prevent heart attacks and damaging strokes.

Other studies highlight the benefits of mung beans for both hypertension and LDL cholesterol reduction.

Another study reported in the journal BMC Complementary and Alternative Medicine showed that mung beans suppress the growth of liver and highly aggressive cervical cancer lines.

This was done through multiple mechanisms, including cytotoxicity, inducing anti-cancer cytokines, halting cancer cell cycle, and triggering apoptosis.

These beneficial modes of action might be responsible for mung beans protection against other cancers as well.

See the article here:

High blood pressure: The tiny bean which relaxes blood vessels to help lower hypertension - Express